Fiona Glassman

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Timothy Craig, Avner Reshef, H Henry Li et al. · The Lancet · 2023 · 94 citations

Thrombosis, Hypertension, Cardiovascular Disease +8

Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312)

Dipti Pawaskar, Xi Chen, Fiona Glassman et al. · Clinical and Translational Science · 2021 · 18 citations · Full text

Translational Medicine, Pharmacokinetic Modeling, Drug Discovery +14

Phosphatidylserine Is Not Just a Cleanup Crew but Also a Well-Meaning Teacher

Fiona Glassman, Jennifer L. Schneider, Radha Ramakrishnan et al. · Journal of Pharmaceutical Sciences · 2018 · 16 citations · Full text

Teacher Education, Well-meaning Teacher, Teaching +4

Subcutaneous administration of Lyso-phosphatidylserine nanoparticles induces immunological tolerance towards Factor VIII in a Hemophilia A mouse model

Fiona Glassman, Sathy V. Balu‐Iyer · International Journal of Pharmaceutics · 2018 · 16 citations

Inflammation, Nanomedicine, Allergy +9

Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins

Nhan H. Nguyen, Fiona Glassman, Robert Dingman et al. · Scientific Reports · 2021 · 14 citations · Full text